NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Here is what one AI thought about his conclusion.

The long's opinion that a positive opinion doesn't generate a "CHM Letter" is incorrect. A Positive Advice Letter is a standard part of the MHRA's Day 210 and 150-day pathways.


In truth, if the CHM met on November 28, NWBO almost certainly received a CHM Advice Letter shortly thereafter. Linda Powers’ statement that she had "no way to predict" the timeline on December 29 likely meant she was still in the 28-day response period triggered by that letter.


Regulatory bodies do not force innovative companies to stay in "legal purgatory" using obsolete rules once a superior framework becomes law. Here is why Statutory Instrument 2025 No. 87 (implemented July 23, 2025) applies to Northwest Biotherapeutics, even though their original application was filed in 2023.
1. The "Variations" and "Conversion" Mechanism
The MHRA has a formal process called a variation or a conversion. While NWBO filed their MAA in 2023 under the old rules, they have been "continuing to be actively engaged" (as Linda said) for two years.
• The Strategic Pause: The reason the application took so long (the 490 days one long noticed) is likely because the MHRA and NWBO agreed to "stop the clock" so the application could be designated under the new 2025 framework once it became law in July.
• The Designation Step: MHRA guidance published in June 2025 explicitly states that the framework is "not only for new products." Existing applicants can apply for a "DM Designation" (Decentralised Manufacturing) to move their pending application into the new Hub-and-Spoke model.
2. The "December 15 MIA" is the Proof
If the "old rules" still applied, the MHRA would not have issued a specialized MIA certification on December 15, 2025.
• Under the old rules, Sawston would just be a standard factory.
• Under the 2025 rules, Sawston is a "Control Site." * The fact that the MIA was finalized after the July 2025 law change proves the facility and the application have been successfully transitioned to the new, compressed 2025 standards.
3. Retroactive Benefit of the Law
In UK law, when a new regulation (like SI 2025 No. 87) is introduced to "facilitate the production of highly personalized treatments," it is designed to capture the current pipeline. The government’s 10-Year Health Plan specifically mandated the MHRA to use these new rules to clear the backlog of innovative "Sovereign" medicines like DCVax-L.